Gender Differences in the Metabolic Effects of Uric Acid
Hyperuricemia
About this trial
This is an interventional basic science trial for Hyperuricemia
Eligibility Criteria
Inclusion Criteria:
- Men and women with characteristics of the metabolic syndrome.
- 40-70 years of age
- Overweight/obese subjects with BMI 25.1 - 40.0 kg/m2
- Pre-diabetes defined as fasting glucose 100 - 125 mg/dL or 2h glucose 140 - 200 mg/dL
- Habitual diets containing ≥ 13.0% of energy from added sugars
- Serum uric acid ≥ 7.0 mg/dL for men and women
Exclusion Criteria:
- Renal dysfunction (defined by glomerular filtration rate [GFR] <60), abnormal thyroid function or liver disease
- Use of diuretics or azathioprine
- Diabetes defined as fasting glucose ≥ 125 mg/dL or HbA1c ≥ 7%
- Use of medications that interfere with lipid, protein, or carbohydrate metabolism, or occasional or regular tobacco use
- Habitual diets with low content of added sugars (<5% of total energy)
- History of gout , gouty arthritis, or uncontrolled hypertension
- Pregnant
- Vegetarian food restrictions (the diets consumed contain some meat, eggs and dairy)
- Alcohol intake: females > 70 g/wk, males >140 g/wk
- Inability to have an MRI
Sites / Locations
- University of Missouri
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
No Intervention
low-fructose diet
allopurinol treatment
control arm
Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.